The Health Care Blog, November 23, 2016. Find out why NCHR president is worried about the 21st Century Cures Act and cautions strongly against its hasty passage in lame-duck session.
Read More »Our Interviews, Blogs & OpEds
Does the FDA Have a High Enough Standard for Drug Approvals?
STAT News, September 28, 2016. Is the Food and Drug Administration’s approval process broken? At a HUBweek panel hosted by STAT, experts explored that question in light of the FDA’s decision last week to approve a controversial drug for Duchenne muscular dystrophy, a rare disease.
Read More »Pro and Con: Experience Well-Suits Her to Deliver Affordable Care to All
Southcoast Today and others, September 23-25, 2016. Published in newspapers across the country, this syndicated column discusses the changes needed to improve the Affordable Care Act.
Read More »21st Century Cures Act: Yes or No? No: Act’s Promise of Quick Cures Is a Brew of Ultra-Hype Mixed With Snake Oil
Chicago Tribune, July 21, 2016. If you or a loved one has a deadly disease, whether it is cancer or a rare disease, you deserve treatments that work. If experimental drugs are your only hope, they should be free as part of a study that you can choose to participate in.
Read More »Congress Shouldn’t Pass the 21st Century Cures Act in a Summer Rush
Health Affairs, July 11, 2016. The full Senate may in the next few days consider companion legislation to the 21st Century Cures Act that passed the House last year. The legislation—currently 19 separate bills—makes substantial changes to the way the Food and Drug Administration (FDA) approves drugs and devices. The legislation, while containing some useful measures, is flawed. Instead of hastily agreeing to it, Congress should postpone consideration until 2017 and attach the best of the 19 bills (see below) to must-pass legislation on FDA funding through industry user fees.
Read More »